Literature DB >> 20491810

Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy.

Je Hyun Seo1, Jeong-Min Hwang, Sung Sup Park.   

Abstract

PURPOSE: To investigate if antituberculosis medication including ethambutol could be a possible epigenetic factor in visual loss in Leber's hereditary optic neuropathy (LHON).
METHODS: The authors reviewed the medical records of 46 patients registered at Bundang Seoul National University Hospital from 2002 to 2006, who developed the typical clinical neuro-ophthalmologic features of LHON and possessed a mtDNA mutation at nucleotide 11778, 14484, 3460 or 4171.
RESULTS: Three of the 46 patients developed visual loss while taking antituberculosis medication. These three patients had the mtDNA 11778 mutation with a mean age of 32.7 years at the onset of visual loss, whereas the mean age of other 43 patients was 21.2 years. One of these three patients was female.
CONCLUSION: Antituberculosis medication may be an epigenetic factor of LHON in patients with a primary LHON mutation. This risk should be recognized by physicians and LHON carriers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20491810     DOI: 10.1111/j.1442-9071.2010.02240.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  10 in total

1.  Parsing the differences in affected with LHON: genetic versus environmental triggers of disease conversion.

Authors:  Valerio Carelli; Pio d'Adamo; Maria Lucia Valentino; Chiara La Morgia; Fred N Ross-Cisneros; Leonardo Caporali; Alessandra Maresca; Paola Loguercio Polosa; Piero Barboni; Annamaria De Negri; Federico Sadun; Rustum Karanjia; Solange R Salomao; Adriana Berezovsky; Filipe Chicani; Milton Moraes; Milton Moraes Filho; Rubens Belfort; Alfredo A Sadun
Journal:  Brain       Date:  2015-12-10       Impact factor: 13.501

2.  Sibling Ethambutol Optic Chiasmopathy.

Authors:  Viran Jayanetti; Michael Rossiter-Thornton; Domit Azar; Clare L Fraser
Journal:  Neuroophthalmology       Date:  2017-05-30

Review 3.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 4.  Pathophysiology of Conversion to Symptomatic Leber Hereditary Optic Neuropathy and Therapeutic Implications: a Review.

Authors:  Alvaro J Mejia-Vergara; Nicolas Seleme; Alfredo A Sadun; Rustum Karanjia
Journal:  Curr Neurol Neurosci Rep       Date:  2020-04-15       Impact factor: 5.081

5.  Leber's hereditary optic neuropathy following unilateral painful optic neuritis: a case report.

Authors:  Chaeyeon Lee; Kyung-Ah Park; Ga-In Lee; Sei Yeul Oh; Ju-Hong Min; Byoung Joon Kim
Journal:  BMC Ophthalmol       Date:  2020-05-18       Impact factor: 2.209

Review 6.  Mitochondrial metabolism and DNA methylation: a review of the interaction between two genomes.

Authors:  Amanda F C Lopes
Journal:  Clin Epigenetics       Date:  2020-11-23       Impact factor: 6.551

7.  Ethambutol-induced conversion in Leber's hereditary optic neuropathy: 6 years follow-up.

Authors:  Mayur R Moreker; Tanuj R Sharma; Satish V Khadilkar
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

8.  Bilateral paediatric optic neuropathy precipitated by vitamin B12 deficiency and a novel mitochondrial DNA mutation.

Authors:  Assad Jalil; Hasan Anzar Usmani; Muhammad Irfan Khan; Emma L Blakely; Robert W Taylor; Grace Vassallo; Jane Ashworth
Journal:  Int Ophthalmol       Date:  2013-04-10       Impact factor: 2.031

9.  Leber Hereditary Optic Neuropathy Associated with Bilateral Macular Holes.

Authors:  Yoshiaki Shimada; Masayuki Horiguchi
Journal:  Neuroophthalmology       Date:  2016-03-09

10.  Raised intraocular pressure as a potential risk factor for visual loss in Leber Hereditary Optic Neuropathy.

Authors:  Anais Thouin; Philip G Griffiths; Gavin Hudson; Patrick F Chinnery; Patrick Yu-Wai-Man
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.